TRAIL R2/DR5/TNFRSF10B hFc Chimera, Human
TRAIL R2/DR5/TNFRSF10B HFc Chimera, Human

Immobilized Human Trail, No Tag at 2 μg /ml(100 μl/well) on the plate. Dose response curve for TRAIL R2/DR5/TNFRSF10B hFc Chimera, Human, hFc Tag with the EC50 of 9.8ng/ml determined by ELISA.

TRAIL R2/DR5/TNFRSF10B HFc Chimera, Human

The purity of TRAIL R2/DR5/TNFRSF10B hFc Chimera, Human is greater than 95% as determined by SEC-HPLC.

TRAIL R2/DR5/TNFRSF10B HFc Chimera, Human

TRAIL R2/DR5/TNFRSF10B hFc Chimera, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

TRAIL R2/DR5/TNFRSF10B hFc Chimera, Human

DR5, also called TRAIL R2, TRICK 2, TNFRSF10B, and MK is a type 1 TNF R superfamily, membrane protein which is a receptor for TRAIL (APO2 ligand). DR5 is a receptor for the cytotoxic ligand TNFSF10/TRAIL. The adapter molecule FADD recruits caspase-8 to the activated receptor. The resulting death-inducing signaling complex (DISC) performs caspase-8 proteolytic activation which initiates the subsequent cascade of caspases (aspartate-specific cysteine proteases) mediating apoptosis.
Z05912
¥52,232.00

Ask us a question
Product Introduction
Species Human
Protein Construction
TRAIL R2/DR5/TNFRSF10B (Ile56-Glu182)
Accession # O14763-1		 hFc
N-term C-term
Purity > 95% as determined by Bis­Tris PAGE 
Endotoxin Level Less than 1EU per μg by the LAL method.
Biological Activity Measured by its binding ability in a functional ELISA. Test result was comparable to standard batch.
Expression System HEK293
Theoretical Molecular Weight 41.1 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 50-55 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22μm filtered solution in 50mM Tris, 100mM NaCl (pH 7.5).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles.

Examples
  • TRAIL R2/DR5/TNFRSF10B HFc Chimera, Human
    • TRAIL R2/DR5/TNFRSF10B HFc Chimera, Human

    Immobilized Human Trail, No Tag at 2 μg /ml(100 μl/well) on the plate. Dose response curve for TRAIL R2/DR5/TNFRSF10B hFc Chimera, Human, hFc Tag with the EC50 of 9.8ng/ml determined by ELISA.

  • TRAIL R2/DR5/TNFRSF10B HFc Chimera, Human
    • TRAIL R2/DR5/TNFRSF10B HFc Chimera, Human

    The purity of TRAIL R2/DR5/TNFRSF10B hFc Chimera, Human is greater than 95% as determined by SEC-HPLC.

  • TRAIL R2/DR5/TNFRSF10B HFc Chimera, Human
    • TRAIL R2/DR5/TNFRSF10B HFc Chimera, Human

    TRAIL R2/DR5/TNFRSF10B hFc Chimera, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.


Background
Target Background DR5, also called TRAIL R2, TRICK 2, TNFRSF10B, and MK is a type 1 TNF R superfamily, membrane protein which is a receptor for TRAIL (APO2 ligand). DR5 is a receptor for the cytotoxic ligand TNFSF10/TRAIL. The adapter molecule FADD recruits caspase-8 to the activated receptor. The resulting death-inducing signaling complex (DISC) performs caspase-8 proteolytic activation which initiates the subsequent cascade of caspases (aspartate-specific cysteine proteases) mediating apoptosis.
Synonyms CD262; DR5; DR5TRICK2B; Fas-like protein; KILLER/DR5; TNFRSF10B; TRAIL R2; TRAIL receptor 2; TRAILR2; TRICK2; TRICK2A; TRICKB; ZTNFR9; KILLER

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.